MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
11/11/16MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
NASDAQ GS | MYOK (Common Stock)
$16.50 + 0.55
12/02/164:01 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.